• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Resources

      For healthcare professionals

      BOTOX® Dosage and Administration Guide

      This guide provides information on the recommended dosage and administration of BOTOX® for overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). The recommended position for injection sites and additional information specific to each indication is also included, along with important safety information.

      To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® Dosage and Administration Guide.

      BOTOX® Procedure Video for Overactive Bladder

      This video provides information on how to administer BOTOX® injections for overactive bladder (OAB). Marcus Drake, Professor of Physiological Urology at the Bristol Urological Institute at Bristol University, talks through patient selection, how to prepare and administer BOTOX® injections and how to follow up with patients.


      Educational resources for healthcare professionals

      BOTOX® (botulinum toxin type A) for the management of bladder dysfunctions

      These educational modules have been developed to support healthcare professionals who manage patients with overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).

      These modules are designed to be used at peer-to-peer meetings; presented either by a healthcare professional or by an AbbVie Key Account Manager. If you are interested in discussing these modules further, please submit your details on the Contact us page. Tick the appropriate box which relates to the module(s) you are interested in and a member of the Abbvie team will be in contact with you.

      Prevalence, diagnosis and patient selection

      • Review of the definition of OAB and the prevalence of this condition
      • The definition and aetiology of NDO
      • The impact of OAB on patients’ quality of life
      • How the impact of OAB on QoL is measured
      • The economic impact of OAB

      The science of overactive bladder and neurogenic detrusor overactivity

      • Review of normal reflex and central control of the bladder
      • Review of neurotransmitters and neuropeptides involved in bladder control
      • The motor and sensory pathways associated with OAB symptoms
      • The proposed pathophysiological mechanisms underlying OAB and NDO

      Management guidelines for overactive bladder and neurogenic detrusor overactivity

      • An overview of the assessment and diagnosis of OAB and various guideline recommendations
      • An overview of the assessment and diagnosis of NDO and urodynamic guidelines
      • Review the current OAB treatment guidelines including use of BOTOX®, anticholinergics and surgical procedures
      • Review the current NDO treatment guidelines including use of BOTOX®, anticholinergics and surgical procedures

      Resources for your patients

      Patient Guide for the Treatment of Overactive Bladder with BOTOX®

      To support your overactive bladder (OAB) patients treated with BOTOX®, this guide provides information on how BOTOX® works, what to expect before and after treatment and any potential side-effects.

      The information in this guide does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.

      To receive a copy of this guide, please submit your details on the Contact Us page and tick Overactive Bladder Patient Guide.

      NDO: neurogenic detrusor overactivity; OAB: overactive bladder.

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.5

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan Ltd. Data on file 014

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: April 2022. UK-BUO-220018.